Principal Financial Group Inc. Purchases 43,589 Shares of Privia Health Group, Inc. $PRVA

Key Points

• Principal Financial Group raised its stake in Privia Health by 1.6%, buying 43,589 shares to own 2,787,802 shares (about 2.27% of the company), and institutional investors collectively hold roughly 94.48% of PRVA.
• Privia reported Q1 revenue of $603.9M (vs. ~ $561M consensus) and EPS of $0.19 (vs. $0.08 consensus), with management reiterating FY‑2026 revenue guidance of approximately $2.4–$2.5B.
• Insiders have been selling recently—CFO and CEO transactions among 274,255 shares sold (~$6.3M) in the last 90 days—which may weigh on near‑term sentiment even as analysts maintain a consensus "Moderate Buy" with an average target of $31.31.

Principal Financial Group Inc. raised its position in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 1.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,787,802 shares of the company's stock after buying an additional 43,589 shares during the quarter. Principal Financial Group Inc. owned about 2.27% of Privia Health Group worth $66,099,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of PRVA. Royal Bank of Canada increased its holdings in Privia Health Group by 63.5% in the 1st quarter. Royal Bank of Canada now owns 245,633 shares of the company's stock valued at $5,514,000 after buying an additional 95,371 shares during the period. AQR Capital Management LLC increased its holdings in Privia Health Group by 24.7% in the 1st quarter. AQR Capital Management LLC now owns 40,781 shares of the company's stock valued at $916,000 after buying an additional 8,068 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Privia Health Group by 3.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 118,764 shares of the company's stock valued at $2,666,000 after buying an additional 3,714 shares during the period. Intech Investment Management LLC increased its holdings in Privia Health Group by 55.1% in the 1st quarter. Intech Investment Management LLC now owns 56,553 shares of the company's stock valued at $1,270,000 after buying an additional 20,082 shares during the period. Finally, Acadian Asset Management LLC bought a new position in Privia Health Group in the 1st quarter valued at about $154,000. 94.48% of the stock is owned by institutional investors.

Analyst Ratings Changes

PRVA has been the topic of several recent analyst reports. Barclays raised their target price on shares of Privia Health Group from $23.00 to $25.00 and gave the company an "equal weight" rating in a report on Wednesday, March 25th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Privia Health Group in a report on Friday, March 27th. Piper Sandler reaffirmed an "overweight" rating and set a $36.00 price target on shares of Privia Health Group in a report on Thursday, February 26th. Canaccord Genuity Group lifted their price target on shares of Privia Health Group from $34.00 to $35.00 and gave the company a "buy" rating in a report on Friday, February 27th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a $32.00 price target on shares of Privia Health Group in a report on Thursday, February 26th. Eleven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $31.31.

Insider Buying and Selling

In other news, CFO David Mountcastle sold 1,206 shares of the business's stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $25.00, for a total value of $30,150.00. Following the transaction, the chief financial officer owned 214,847 shares in the company, valued at approximately $5,371,175. The trade was a 0.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Parth Mehrotra sold 26,509 shares of the business's stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $22.11, for a total transaction of $586,113.99. Following the completion of the transaction, the chief executive officer owned 555,443 shares in the company, valued at $12,280,844.73. This trade represents a 4.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 274,255 shares of company stock worth $6,299,092 in the last ninety days. Company insiders own 5.70% of the company's stock.

Privia Health Group Stock Performance

Shares of Privia Health Group stock opened at $23.99 on Friday. The firm's 50 day moving average is $22.73 and its 200 day moving average is $23.34. Privia Health Group, Inc. has a 1 year low of $18.77 and a 1 year high of $26.51. The firm has a market capitalization of $3.01 billion, a PE ratio of 141.12, a price-to-earnings-growth ratio of 1.50 and a beta of 0.96.

Privia Health Group (NASDAQ:PRVA - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.08 by $0.11. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. The business had revenue of $603.85 million for the quarter, compared to the consensus estimate of $560.99 million. During the same period last year, the company earned $0.22 EPS. The firm's revenue was up 25.8% compared to the same quarter last year. As a group, research analysts anticipate that Privia Health Group, Inc. will post 0.37 earnings per share for the current year.

Privia Health Group News Roundup

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Reported Q1 results showed material revenue outperformance (company: $603.9M vs. street ~$561M) and management reiterated FY‑2026 revenue guidance (~$2.4B–$2.5B), supporting growth expectations. Privia Health Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Some previews and follow‑ups highlight key metrics investors will parse (patient volumes, margin trends, and guidance drivers) rather than create a clear directional read until the conference call details are digestible. What to expect from Privia Health’s (PRVA) Q1 earnings
• Neutral Sentiment: Coverage is mixed on the underlying EPS figure (some outlets cite a beat while others report a miss), creating short‑term noise as investors reconcile the company release, third‑party estimates and timing/adjustments. Privia Health (PRVA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
• Negative Sentiment: Insider selling from senior executives (CFO sales under a 10b5‑1 plan) has been disclosed recently; while pre‑arranged plans lessen governance concerns, the transactions can pressure near‑term sentiment. Privia Health (PRVA) Insider Selling
• Negative Sentiment: Director share sales (also under 10b5‑1 plans) add to the near‑term supply narrative and may offset some of the positive reaction to top‑line strength. Director Matthew Shawn Morris Sells Shares

Privia Health Group Company Profile

Privia Health Group NASDAQ: PRVA is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.